Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works..
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:369 |
|---|---|
| Enthalten in: |
Science (New York, N.Y.) - 369(2020), 6504 vom: 07. Aug., Seite 643-650 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.08.2020 Date Revised 11.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/science.abc5902 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311199658 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311199658 | ||
| 003 | DE-627 | ||
| 005 | 20240211231829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/science.abc5902 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM311199658 | ||
| 035 | |a (NLM)32540902 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brouwer, Philip J M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.08.2020 | ||
| 500 | |a Date Revised 11.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. | ||
| 520 | |a The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 650 | 7 | |a Broadly Neutralizing Antibodies |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Receptors, Coronavirus |2 NLM | |
| 650 | 7 | |a Receptors, Virus |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Caniels, Tom G |e verfasserin |4 aut | |
| 700 | 1 | |a van der Straten, Karlijn |e verfasserin |4 aut | |
| 700 | 1 | |a Snitselaar, Jonne L |e verfasserin |4 aut | |
| 700 | 1 | |a Aldon, Yoann |e verfasserin |4 aut | |
| 700 | 1 | |a Bangaru, Sandhya |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Jonathan L |e verfasserin |4 aut | |
| 700 | 1 | |a Okba, Nisreen M A |e verfasserin |4 aut | |
| 700 | 1 | |a Claireaux, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Kerster, Gius |e verfasserin |4 aut | |
| 700 | 1 | |a Bentlage, Arthur E H |e verfasserin |4 aut | |
| 700 | 1 | |a van Haaren, Marlies M |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Burger, Judith A |e verfasserin |4 aut | |
| 700 | 1 | |a Schermer, Edith E |e verfasserin |4 aut | |
| 700 | 1 | |a Verheul, Kirsten D |e verfasserin |4 aut | |
| 700 | 1 | |a van der Velde, Niels |e verfasserin |4 aut | |
| 700 | 1 | |a van der Kooi, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a van Schooten, Jelle |e verfasserin |4 aut | |
| 700 | 1 | |a van Breemen, Mariëlle J |e verfasserin |4 aut | |
| 700 | 1 | |a Bijl, Tom P L |e verfasserin |4 aut | |
| 700 | 1 | |a Sliepen, Kwinten |e verfasserin |4 aut | |
| 700 | 1 | |a Aartse, Aafke |e verfasserin |4 aut | |
| 700 | 1 | |a Derking, Ronald |e verfasserin |4 aut | |
| 700 | 1 | |a Bontjer, Ilja |e verfasserin |4 aut | |
| 700 | 1 | |a Kootstra, Neeltje A |e verfasserin |4 aut | |
| 700 | 1 | |a Wiersinga, W Joost |e verfasserin |4 aut | |
| 700 | 1 | |a Vidarsson, Gestur |e verfasserin |4 aut | |
| 700 | 1 | |a Haagmans, Bart L |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Andrew B |e verfasserin |4 aut | |
| 700 | 1 | |a de Bree, Godelieve J |e verfasserin |4 aut | |
| 700 | 1 | |a Sanders, Rogier W |e verfasserin |4 aut | |
| 700 | 1 | |a van Gils, Marit J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science (New York, N.Y.) |d 1880 |g 369(2020), 6504 vom: 07. Aug., Seite 643-650 |w (DE-627)NLM000023450 |x 1095-9203 |7 nnns |
| 773 | 1 | 8 | |g volume:369 |g year:2020 |g number:6504 |g day:07 |g month:08 |g pages:643-650 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/science.abc5902 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 369 |j 2020 |e 6504 |b 07 |c 08 |h 643-650 | ||